{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"SYMPHONY-1: A PHASE 1B\/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED\/REFRACTORY FOLLICULAR LYMPHOMA","item":"https:\/\/www.regionalcancercare.org\/trials\/symphony-1-a-phase-1b-3-double-blind-randomized-active-controlled-3-stage-biomarker-adaptive-study-of-tazemetostat-or-placebo-in-combination-with-lenalidomide-plus-rituximab-in-subjects-with-rela-2\/#breadcrumbitem"}]}